Drug Profile
Research programme: anti-infectives - Genelabs Technologies
Alternative Names: Anti-infectives research programme - Genelabs; DNA-binding polyheterocyclic compounds - Genelabs; GL 047374; GL 118172; GL 243287; GL 359986; GL 478057; GL 48087; GL 521997; GL 548043; GL 568816; GL 579225; GL 663142; GL 700241; GL 701649; GL 703027; GL 832293; GL 886217; GL 898298; Pyrrole tetraamides research programme - GenelabsLatest Information Update: 04 Mar 2008
Price :
$50
*
At a glance
- Originator Genelabs Technologies
- Class Amides; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections; Mycoses
Most Recent Events
- 18 Nov 2004 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 14 Jun 2002 Preclinical trials in Mycoses in USA (unspecified route)
- 07 Mar 2002 Early research in Bacterial infections in USA (unspecified route)